fasenra soluzione iniettabile
astrazeneca ag - benralizumabum - soluzione iniettabile - benralizumabum 30 mg, histidinum, histidini hydrochloridum monohydricum, trehalosum dihydricum, polysorbatum 20, aqua ad iniectabile ad solutionem pro 1 ml. - schweres eosinophiles asma - biotechnologika
sitagliptin / metformin hydrochloride mylan
mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabete mellito, tipo 2 - farmaci usati nel diabete - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , triplice terapia di associazione) in aggiunta alla dieta e all'esercizio fisico in pazienti non adeguatamente controllati il loro dosaggio massimo tollerato di metformina ed una sulfonilurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
vildagliptin / metformin hydrochloride accord
accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabete mellito, tipo 2 - farmaci usati nel diabete - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 e 5. 1 per i dati disponibili su diverse combinazioni).
sitagliptin / metformin hydrochloride sun
sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabete mellito, tipo 2 - farmaci usati nel diabete - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , triplice terapia di associazione) in aggiunta alla dieta e all'esercizio fisico in pazienti non adeguatamente controllati il loro dosaggio massimo tollerato di metformina ed una sulfonilurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
potassio cloruro
b. braun melsungen ag - potassio cloruro - potassio cloruro
ytracis
cis bio international - yttrium (90y) chloride - imaging dei radionuclidi - radiofarmaci diagnostici - da utilizzare solo per la marcatura radioattiva di molecole carrier espressamente sviluppate e autorizzate per la radiomarcatura con questo radionuclide. radiopharmaceutical precursor - not intended for direct application to patients.
yttriga
eckert ziegler radiopharma gmbh - yttrium (90y) chloride - imaging dei radionuclidi - radiofarmaci diagnostici - deve essere utilizzato solo per la radiomarcatura di molecole, che sono stati specificamente sviluppate e autorizzate per la radiomarcatura con questo radionuclide. radiofarmaco precursore - non destinati all'uso diretto in pazienti.
xofigo 1100 kbq/ml ra-223-dichlorid soluzione iniettabile
bayer (schweiz) ag - radii(223-ra) dichloridum per kalibrierungszeitpunkt - soluzione iniettabile - radii(223-ra) dichloridum zum kalibrierungszeitpunkt 6600 kbq, natrii chloridum, natrii citras dihydricus, acidum hydrochloridum, aqua ad iniectabile, q.s. ad solutionem pro 6 ml corresp. natrium 26.4 mg. - sintomatico in caso di metastasi ossee kastrationsresistentem prostatico - radiopharmazeutika
lumeblue (previously known as methylthioninium chloride cosmo)
alfasigma s.p.a. - cloruro di metiltioninio - colorectal neoplasms; colonoscopy - other diagnostic agents - lumeblue is indicated as a diagnostic agent enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy.
lutetium (177lu) chloride billev (previously illuzyce)
billev pharma aps - lutetium (177lu) chloride - imaging dei radionuclidi - radiofarmaci terapeutici - lutetium (177lu) chloride billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. it is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177lu) chloride.